Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 583

1.

Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.

Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA.

J Clin Psychopharmacol. 1996 Apr;16(2):121-9.

PMID:
8690827
2.

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.

Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ.

J Clin Psychiatry. 1994 Jul;55(7):301-5.

PMID:
8071291
3.

Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.

Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E.

J Clin Psychopharmacol. 1997 Feb;17(1):4-10. Erratum in: J Clin Psychopharmacol 1997 Oct;17(5):340. J Clin Psychopharmacol 1997 Oct;17(5):436.

PMID:
9004050
4.

Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.

Mundo E, Maina G, Uslenghi C.

Int Clin Psychopharmacol. 2000 Mar;15(2):69-76.

PMID:
10759337
5.

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

Goodman WK, Kozak MJ, Liebowitz M, White KL.

Int Clin Psychopharmacol. 1996 Mar;11(1):21-9.

PMID:
8732310
6.

A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.

Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB.

Int Clin Psychopharmacol. 1997 May;12(3):131-6.

PMID:
9248868
7.

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.

Piccinelli M, Pini S, Bellantuono C, Wilkinson G.

Br J Psychiatry. 1995 Apr;166(4):424-43.

PMID:
7795913
8.
9.

Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.

Mundo E, Rouillon F, Figuera ML, Stigler M.

Hum Psychopharmacol. 2001 Aug;16(6):461-468.

PMID:
12404554
10.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
11.
12.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
13.
14.

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC.

J Psychopharmacol. 2010 Mar;24(3):297-307. doi: 10.1177/0269881108099423. Epub 2009 Jan 22.

PMID:
19164490
15.

Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.

Apter A, Ratzoni G, King RA, Weizman A, Iancu I, Binder M, Riddle MA.

J Am Acad Child Adolesc Psychiatry. 1994 Mar-Apr;33(3):342-8.

PMID:
8169178
16.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
17.
18.

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.

Eur Neuropsychopharmacol. 2005 Jan;15(1):69-74.

PMID:
15572275
19.

Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.

Mundo E, Guglielmo E, Bellodi L.

Int Clin Psychopharmacol. 1998 Sep;13(5):219-24.

PMID:
9817627
20.

Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.

Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C, Matsunaga H.

Psychiatry Clin Neurosci. 2004 Aug;58(4):427-33.

Supplemental Content

Support Center